Sector News

EMA chief Rasi kicked out as tribunal annuls appointment

November 14, 2014
Life sciences
The European Medicines Agency’s executive director Guido Rasi has been forced to step down after his appointment, made three years, was annulled by a EU panel.
 
The European Union Civil Service Tribunal has ruled on an appeal by an individual against the selection procedure in 2011 for the appointment of executive director of the EMA. The unnamed person brought the case in January 2012 following the decision by the European Commission not to include him on the shortlist of candidates.
 
The court has, “on purely formal grounds”, annulled the Commission’s decision of adopting a shortlist and as a consequence, the choice of Dr Rasi (pictured) has also been annulled.
 
Sir Kent Woods, chair of the EMA management board, noted “with regret” the tribunal’s judgement, saying “it is important to remember that the ruling is about a procedural formality. It is not a reflection on Guido Rasi’s competence or ability to run the agency, something which he has done successfully since November 2011.”
 
The European Commission and EMA are both taking legal advice. “Pending further decisions”, Andreas Pott, the agency’s deputy executive director, will take over.
 
By Kevin Grogan
 
Source: Pharma Times
 

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.